Ads
related to: duration of response cancer risk score
Search results
Results From The WOW.Com Content Network
The mean response rate for new cancer drugs approved by the U.S. Food and Drug Administration, expressed as relative risk, ranges between 1.38x [3] and 2.37x. [ 4 ] See also
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
The sum of the points allotted correlates with the following risk groups: Low risk (0-1 points) - 5 and 10-year survivals of 91% and 71%, respectively; Intermediate risk (2 points) - 5 and 10-year survivals of 78% and 51%, respectively; High risk (3-5 points) - 5 and 10-year survivals of 53% and 36%, respectively
Cancer slope factors (CSF) are used to estimate the risk of cancer associated with exposure to a carcinogenic or potentially carcinogenic substance. A slope factor is an upper bound, approximating a 95% confidence limit , on the increased cancer risk from a lifetime exposure to an agent by ingestion or inhalation .
Time is indicated by the variable "time", which is the survival or censoring time; Event (recurrence of aml cancer) is indicated by the variable "status". 0 = no event (censored), 1 = event (recurrence) Treatment group: the variable "x" indicates if maintenance chemotherapy was given; The last observation (11), at 161 weeks, is censored.
2.1.1 Risk assessment. 2.1.2 ... dependent on the number of cancer cells. Response to treatment is thus associated with reduced levels of S100-beta in the blood of ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
In statistics, median follow-up is the median time between a specified event and the time when data on outcomes are gathered. The concept is used in cancer survival analyses. [citation needed] Many cancer studies aim to assess the time between two events of interest, such as from treatment to remission, treatment to relapse, or diagnosis to death.